Safety and immunogenicity of co-administered #meningococcal serogroup B (#4CMenB) vaccine

📌 4CMenB co-administration is not associated with significant safety concerns or clinically relevant immunological interferences.

📌 The increased reactogenicity(e.g., fever)associated with 4CMenB co-administration can be managed with prophylactic paracetamol in children.

📌 4CMenB co-administration has the potential to maximize vaccine coverage and improve protection against IMD.

https://www.tandfonline.com/doi/full/10.1080/21645515.2023.2245705

A comprehensive review of clinical and real-world safety data for the four-component serogroup B #meningococcal #vaccine (#4CMenB)

#Bexsero

📌 Neisseria meningitidis causes invasive meningococcal disease and, globally, significant morbidity, with serogroup B (MenB) being the most common cause of endemic disease and outbreaks in several regions

📌 Abundant safety data from can help reassure individuals and healthcare providers on the use of 4CMenB.

A comprehensive review of clinical and real-world safety data for the four-component serogroup B #meningococcal vaccine (#4CMenB)

📌 The four-component serogroup B meningococcal vaccine 4CMenB (Bexsero®, GSK) was licensed in 2013 and has acquired substantial safety evidence through clinical trial and real-world data.

📌This comprehensive review of safety data, from 9 years of 4CMenB use shows no significant safety issues in a variety of age groups.

https://www.tandfonline.com/doi/full/10.1080/14760584.2023.2222015

Effectiveness of a #Meningococcal Group B Vaccine (#4CMenB) in #Children

https://www.nejm.org/doi/10.1056/NEJMoa2206433

New research article in The Lancet Child & Adolescent Health>

Outcomes of meningococcal serogroup B disease in children after implementation of routine infant #4CMenB vaccination in England: an active, prospective, national surveillance study

https://www.thelancet.com/journals/lanchi/article/PIIS2352-4642(22)00379-0/fulltext

#meningitis #sepsis #meningococcus #Neisseria